ABBVIE
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD
- Conditions
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 300
- Registration Number
- NCT04704921
- Locations
- ๐บ๐ธ
Long Island Vitreoretinal Consultants - Great Neck, Great Neck, New York, United States
๐บ๐ธRetina Consultants of Orange County - Fullerton Office, Fullerton, California, United States
๐บ๐ธOrange County Retina Medical Group, Santa Ana, California, United States
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
- Conditions
- Interventions
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 596
- Registration Number
- NCT04686136
- Locations
- ๐บ๐ธ
Mount Vernon Clinical Research /ID# 226249, Chattanooga, Tennessee, United States
๐ฉ๐ชNeuropoint GmbH /ID# 226313, Ulm, Germany
๐จ๐ฆOttawa Headache Centre Research Inc /ID# 226451, Ottawa, Ontario, Canada
A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- AbbVie
- Registration Number
- NCT04666675
Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 5
- Registration Number
- NCT04655261
- Locations
- ๐ท๐บ
Tula Regional Clinical Hospital /ID# 231128, Tula, Russian Federation
๐ท๐บRussian Research Institute of Hematology and Transfusiology of the FMBA /ID# 231127, Sankt-Peterburg, Russian Federation
๐ท๐บMoscow State budget healthcare /ID# 226058, Moscow, Moskva, Russian Federation
Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)
- Conditions
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 25
- Registration Number
- NCT04644120
- Locations
- ๐บ๐ธ
Beautiful Minds Clinical Research Center /ID# 228708, Cutler Bay, Florida, United States
๐บ๐ธGlendale Adventist Medical Center /ID# 225188, Glendale, California, United States
๐บ๐ธTriple O Research Institute /ID# 228612, West Palm Beach, Florida, United States
Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease Symptoms in Adult Female Participants With Moderate to Severe Endometriosis-associated Pain
- Conditions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 117
- Registration Number
- NCT04630990
- Locations
- ๐ฎ๐ฑ
Kaplan Medical Center /ID# 224773, Rekhovot, HaMerkaz, Israel
๐ฎ๐ฑSoroka University Medical Center /ID# 224774, Be'er Sheva, HaDarom, Israel
๐ฎ๐ฑYitzhak Shamir Medical Center /ID# 224768, Zerifin, HaMerkaz, Israel
A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois
- Conditions
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1007
- Registration Number
- NCT04611230
- Locations
- ๐บ๐ธ
Great Lakes Clinical Trials /ID# 224874, Chicago, Illinois, United States
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 310
- Registration Number
- NCT04578756
- Locations
- ๐บ๐ธ
Harmonex Neuroscience Research /ID# 234938, Dothan, Alabama, United States
๐บ๐ธPillar Clinical Research /ID# 236434, Bentonville, Arkansas, United States
๐บ๐ธAdvanced Research Center /ID# 241903, Anaheim, California, United States
Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response
- Conditions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 42
- Registration Number
- NCT04577482
- Locations
- ๐ท๐บ
Irkutsk Regional Center for the Prevention and Control of AIDS and Infections /ID# 229509, Irkutsk, Russian Federation
๐ท๐บInfectious Clinical Hosp #1 /ID# 225063, Moscow, Russian Federation
๐ท๐บInfectious Clinical Hospita l#2 /ID# 243217, Nizhniy Novgorod, Russian Federation
A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 413
- Registration Number
- NCT04574492
- Locations
- ๐จ๐ฆ
Dr. Jonathan D. Chan Inc. /ID# 222976, Vancouver, British Columbia, Canada
๐จ๐ฆEastern Regional Health Authority /ID# 223911, St. John's, Newfoundland and Labrador, Canada
๐จ๐ฆFraser Clinical Trials Inc /ID# 225200, New Westminster, British Columbia, Canada